title: Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants.
abstract: BACKGROUND
  This is the first report on the preliminary efficacy of 4 different short-course nucleoside analogue regimens (stavudine [d4T], didanosine [ddI], d4T+ddI, and zidovudine [ZDV]) for the prevention of mother-to-child transmission of HIV-1 (MTCT) in a resource-limited setting.
  
  
  METHODS
  This prospective open-label, randomized 4-arm study (May 1999 to May 2000) conducted in South Africa enrolled 373 women from 34 weeks of gestation; medication was continued through delivery and for 6 weeks to infants. MTCT rates were ascertained at birth, 6, 12, and 24 weeks of age.
  
  
  RESULTS
  Mean maternal HIV-1 RNA levels decreased rapidly on treatment in all groups. At week 4, the mean decrease was 1.91 log10 copies/mL (c/mL) in the d4T+ddI group, 1.33 log10 c/mL in the ddI group, 1.12 log10 c/mL in the d4T group, and 0.76 log10 c/mL in the ZDV group. Among the 362 evaluable mother-infant pairs, 11 infants in the d4T group, 10 in the ddI group, 5 in the ZDV group, and 4 in the d4T+ddI group were infected by 24 weeks of age. Eleven infections occurred in utero. Treatment with d4T and ddI was not associated with lactic acidosis or hepatic steatosis.
  
  
  CONCLUSIONS
  The abbreviated use of nucleoside analogues for the prevention of MTCT appears safe and effective.
authors.affiliation: Perinatal HIV Research Unit, University of the Witwatersrand, South Africa. gray@pixie.co.za
authors.forename: Glenda
authors.initials: G
authors.lastname: Gray
authors.forename: Avye
authors.initials: A
authors.lastname: Violari
authors.forename: James
authors.initials: J
authors.lastname: McIntyre
authors.forename: Boris
authors.initials: B
authors.lastname: Jivkov
authors.forename: Steven
authors.initials: S
authors.lastname: Schnittman
authors.forename: Laurie
authors.initials: L
authors.lastname: Reynolds
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Ledeine
mesh_terms: D000140:Acidosis, Lactic; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005234:Fatty Liver; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D009035:Mothers; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D013019:South Africa; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use; D019562:Viral Load; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D015215:Zidovudine; D018119:Stavudine; D016049:Didanosine